Exact Mass: 624.341

Exact Mass Matches: 624.341

Found 78 metabolites which its exact mass value is equals to given mass value 624.341, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Caribenolide I

(20E)-7-butyl-11,16,23,24,25-pentahydroxy-10,19,20-trimethyl-15-methylidene-8,13,28,29-tetraoxatetracyclo[22.3.1.13,6.012,14]nonacos-20-ene-9,18-dione

C33H52O11 (624.3509)


   

PA(8:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

[(2R)-2-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C33H53O9P (624.3427)


PA(8:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 4-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/8:0)

[(2R)-3-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C33H53O9P (624.3427)


PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/8:0), in particular, consists of one chain of one 4-hydroxy-docosahexaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

[(2R)-2-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C33H53O9P (624.3427)


PA(8:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 7-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/8:0)

[(2R)-3-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C33H53O9P (624.3427)


PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/8:0), in particular, consists of one chain of one 7-hydroxy-docosahexaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

[(2R)-2-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C33H53O9P (624.3427)


PA(8:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 14-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/8:0)

[(2R)-3-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C33H53O9P (624.3427)


PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/8:0), in particular, consists of one chain of one 14-hydroxy-docosahexaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

[(2R)-2-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C33H53O9P (624.3427)


PA(8:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 17-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/8:0)

[(2R)-3-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C33H53O9P (624.3427)


PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/8:0), in particular, consists of one chain of one 17-hydroxy-docosahexaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

PA(8:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C33H53O9P (624.3427)


PA(8:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 16,17-epoxy-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/8:0)

[(2R)-2-(octanoyloxy)-3-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}propoxy]phosphonic acid

C33H53O9P (624.3427)


PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/8:0), in particular, consists of one chain of one 16,17-epoxy-docosapentaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   
   

24-epipetunioside C

24-epipetunioside C

C33H52O11 (624.3509)


   

podecdysone B 25-O-beta-D-glucopyranoside

podecdysone B 25-O-beta-D-glucopyranoside

C33H52O11 (624.3509)


   

26-O-beta-D-glucopyranosyl-22alpha-furosta-5,25(27)-diene-1beta,3beta,11alpha,22alpha,26-pentaol|26-[(beta-D-glucopyranosyl)oxy]-22alpha-hydroxyfurosta-5,25(27)-diene-1beta,3beta,11alpha-triol|helleboroside B

26-O-beta-D-glucopyranosyl-22alpha-furosta-5,25(27)-diene-1beta,3beta,11alpha,22alpha,26-pentaol|26-[(beta-D-glucopyranosyl)oxy]-22alpha-hydroxyfurosta-5,25(27)-diene-1beta,3beta,11alpha-triol|helleboroside B

C33H52O11 (624.3509)


   

(25R)-spirost-7-ene-2alpha,3beta,5alpha,9alpha-tetrol 3-O-beta-D-glucopyranoside

(25R)-spirost-7-ene-2alpha,3beta,5alpha,9alpha-tetrol 3-O-beta-D-glucopyranoside

C33H52O11 (624.3509)


   
   

14-deoxy-14alpha,15alpha-epoxyponasteroside A|brainesteroside A

14-deoxy-14alpha,15alpha-epoxyponasteroside A|brainesteroside A

C33H52O11 (624.3509)


   

solanolactoside B

solanolactoside B

C33H52O11 (624.3509)


   

mandelalide A

mandelalide A

C33H52O11 (624.3509)


   

(5alpha)-pregna-16-en-3beta-ol-20-one 6-O-[alpha-L-rhamnopyranosyl-(1?3)-beta-D-quinovopyranoside]|torvpregnanoside A

(5alpha)-pregna-16-en-3beta-ol-20-one 6-O-[alpha-L-rhamnopyranosyl-(1?3)-beta-D-quinovopyranoside]|torvpregnanoside A

C33H52O11 (624.3509)


   

7-Deepoxy,6-hydroxy,7-chloro,2,3,4,5-tetrahydro-Huratoxin

7-Deepoxy,6-hydroxy,7-chloro,2,3,4,5-tetrahydro-Huratoxin

C34H53ClO8 (624.3429)


   

(25S)-22alpha,25-epoxy-3beta,11alpha-dihydroxyfurost-5-en-26-yl beta-D-glucopyranoside

(25S)-22alpha,25-epoxy-3beta,11alpha-dihydroxyfurost-5-en-26-yl beta-D-glucopyranoside

C33H52O11 (624.3509)


   

Leu Thr Ser Lys Tyr

Leu Thr Ser Lys Tyr

C29H48N6O9 (624.3483)


   

Phe Phe Arg Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanoic acid

C30H44N10O5 (624.3496)


   

Phe Arg Phe Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]-5-carbamimidamidopentanoic acid

C30H44N10O5 (624.3496)


   

Phe Arg Arg Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-phenylpropanoic acid

C30H44N10O5 (624.3496)


   

Arg Phe Phe Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-phenylpropanamido]-5-carbamimidamidopentanoic acid

C30H44N10O5 (624.3496)


   

Arg Phe Arg Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-phenylpropanoic acid

C30H44N10O5 (624.3496)


   

Arg Arg Phe Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-phenylpropanoic acid

C30H44N10O5 (624.3496)


   

Brainesteroside A

3-O-(beta-D-glucopyranosyl)-2beta,3beta,20,22R-tetrahydroxy-14alpha,15alpha-epoxy-5beta-cholest-7-en-6-one

C33H52O11 (624.3509)


   

Spongipregnoloside A

3-O-(alpha-L-rhamnopyranosyl-(1-2)-beta-D-glucopyranosyl)-3beta-hydroxy-pregna-5,16-dien-20-one

C33H52O11 (624.3509)


   

ST 33:2_O7

3-O-alpha-L-rhamnopyranosyl-(1-4)-beta-D-glucopyranosyl)-3beta-hydroxy-pregna-5,16-dien-20-one

C33H52O11 (624.3509)


   

Aspacoside A

(3beta, 5beta)-pregn-16(17)-en-3-ol-20-one 3-O-alpha-l-rhamnopyranosyl-(1-4)-beta-d-glucopyranoside

C33H52O11 (624.3509)


   

Aspacoside B

(3beta, 5beta)-pregn-16(17)-en-3-ol-20-one 3-O-alpha-l-rhamnopyranosyl-(1-2)-beta-d-glucopyranoside

C33H52O11 (624.3509)


   
   

3-[(21S,22S)-26-ethyl-4-hydroxy-16-(1-hydroxyethyl)-12-(hydroxymethyl)-17,19,21-trimethyl-11-(2-methylpropyl)-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid

3-[(21S,22S)-26-ethyl-4-hydroxy-16-(1-hydroxyethyl)-12-(hydroxymethyl)-17,19,21-trimethyl-11-(2-methylpropyl)-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid

C37H44N4O5 (624.3312)


   

PA(8:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

PA(8:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C33H53O9P (624.3427)


   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/8:0)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/8:0)

C33H53O9P (624.3427)


   

PA(8:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

PA(8:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C33H53O9P (624.3427)


   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/8:0)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/8:0)

C33H53O9P (624.3427)


   

PA(8:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

PA(8:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C33H53O9P (624.3427)


   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/8:0)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/8:0)

C33H53O9P (624.3427)


   

PA(8:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

PA(8:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C33H53O9P (624.3427)


   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/8:0)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/8:0)

C33H53O9P (624.3427)


   

PA(8:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

PA(8:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C33H53O9P (624.3427)


   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/8:0)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/8:0)

C33H53O9P (624.3427)


   

Spongipregnoloside B

Spongipregnoloside B

C33H52O11 (624.3509)


   
   
   

PA 18:3/12:3;O

PA 18:3/12:3;O

C33H53O9P (624.3427)


   

PA 22:5/8:1;O

PA 22:5/8:1;O

C33H53O9P (624.3427)


   
   
   
   

ST 27:2;O5;GlcA

ST 27:2;O5;GlcA

C33H52O11 (624.3509)


   

(1's,2r,2's,5'r,6'r,10's,12's,14's)-5'-[(2s,3r,5r)-5,6-dihydroxy-5,6-dimethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

(1's,2r,2's,5'r,6'r,10's,12's,14's)-5'-[(2s,3r,5r)-5,6-dihydroxy-5,6-dimethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

C33H52O11 (624.3509)


   

(1s,2s,4s,6r,7s,8r,9s,11r,12s,13r,14r,16r)-7,9,13-trimethyl-6-[3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-ene-6,11,14,16-tetrol

(1s,2s,4s,6r,7s,8r,9s,11r,12s,13r,14r,16r)-7,9,13-trimethyl-6-[3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-ene-6,11,14,16-tetrol

C33H52O11 (624.3509)


   

1-(2,3-dihydroxy-6-methyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl)-7,8-dihydroxy-9a,11a-dimethyl-1h,2h,4h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-5-one

1-(2,3-dihydroxy-6-methyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl)-7,8-dihydroxy-9a,11a-dimethyl-1h,2h,4h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-5-one

C33H52O11 (624.3509)


   

5-(acetyloxy)-14-(butanoyloxy)-6,10-dihydroxy-3-isopropyl-6,10,14-trimethyl-11-(prop-2-enoyloxy)-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate

5-(acetyloxy)-14-(butanoyloxy)-6,10-dihydroxy-3-isopropyl-6,10,14-trimethyl-11-(prop-2-enoyloxy)-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate

C33H52O11 (624.3509)


   

(1r,3r,9r,10r,13r,15r,21s,23r)-23-{[(2r,3r,4r,5r,6s)-4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl]oxy}-13-hydroxy-15-(hydroxymethyl)-3,10-dimethyl-16,25,26-trioxatricyclo[19.3.1.1⁹,¹²]hexacosa-4,6,18-trien-17-one

(1r,3r,9r,10r,13r,15r,21s,23r)-23-{[(2r,3r,4r,5r,6s)-4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl]oxy}-13-hydroxy-15-(hydroxymethyl)-3,10-dimethyl-16,25,26-trioxatricyclo[19.3.1.1⁹,¹²]hexacosa-4,6,18-trien-17-one

C33H52O11 (624.3509)


   

n-(1-{[(4e,10e,12z)-6,22-dihydroxy-16-methoxy-5,7-dimethyl-18-oxo-25-oxa-19-azatetracyclo[12.9.2.0¹⁵,¹⁹.0²⁰,²⁴]pentacosa-1(24),4,10,12,20,22-hexaen-8-yl]oxy}-1-oxopropan-2-yl)-4-methylpentanimidic acid

n-(1-{[(4e,10e,12z)-6,22-dihydroxy-16-methoxy-5,7-dimethyl-18-oxo-25-oxa-19-azatetracyclo[12.9.2.0¹⁵,¹⁹.0²⁰,²⁴]pentacosa-1(24),4,10,12,20,22-hexaen-8-yl]oxy}-1-oxopropan-2-yl)-4-methylpentanimidic acid

C35H48N2O8 (624.341)


   

6-(2,3-dihydroxy-6-methylheptan-2-yl)-13-hydroxy-7,11-dimethyl-14-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadec-1(18)-en-17-one

6-(2,3-dihydroxy-6-methylheptan-2-yl)-13-hydroxy-7,11-dimethyl-14-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadec-1(18)-en-17-one

C33H52O11 (624.3509)


   

(1r,2r,3r,4s,5r,6s,7s,8r,10s,11s,14s)-5-(acetyloxy)-14-(butanoyloxy)-6,10-dihydroxy-3-isopropyl-6,10,14-trimethyl-11-(prop-2-enoyloxy)-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate

(1r,2r,3r,4s,5r,6s,7s,8r,10s,11s,14s)-5-(acetyloxy)-14-(butanoyloxy)-6,10-dihydroxy-3-isopropyl-6,10,14-trimethyl-11-(prop-2-enoyloxy)-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate

C33H52O11 (624.3509)


   

(1's,2r,2's,5'r,6'r,10's,12's,14's)-5'-[(2s,3r,5s)-5,6-dihydroxy-5,6-dimethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

(1's,2r,2's,5'r,6'r,10's,12's,14's)-5'-[(2s,3r,5s)-5,6-dihydroxy-5,6-dimethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

C33H52O11 (624.3509)


   

(2s,4s,6s,7r,10r,11r,13s,14r,16r)-6-[(2r,3r)-2,3-dihydroxy-6-methylheptan-2-yl]-13-hydroxy-7,11-dimethyl-14-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadec-1(18)-en-17-one

(2s,4s,6s,7r,10r,11r,13s,14r,16r)-6-[(2r,3r)-2,3-dihydroxy-6-methylheptan-2-yl]-13-hydroxy-7,11-dimethyl-14-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadec-1(18)-en-17-one

C33H52O11 (624.3509)


   

(1's,2r,2's,5's,6'r,10's,12'r,14's)-5'-[(2s,3r,5s)-5,6-dihydroxy-5,6-dimethyl-3-{[(2r,3r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

(1's,2r,2's,5's,6'r,10's,12'r,14's)-5'-[(2s,3r,5s)-5,6-dihydroxy-5,6-dimethyl-3-{[(2r,3r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

C33H52O11 (624.3509)


   

5'-(5,6-dihydroxy-5,6-dimethyl-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl)-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

5'-(5,6-dihydroxy-5,6-dimethyl-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl)-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

C33H52O11 (624.3509)


   

1-[(1s,3as,3bs,7s,9ar,9bs,11as)-7-{[(2r,4s,5s)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3s,5r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

1-[(1s,3as,3bs,7s,9ar,9bs,11as)-7-{[(2r,4s,5s)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3s,5r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

C33H52O11 (624.3509)


   

(1s,5ar,7r,8s,9as,11ar)-1-[(2r,3r)-2,3-dihydroxy-6-methyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-7,8-dihydroxy-9a,11a-dimethyl-1h,2h,4h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-5-one

(1s,5ar,7r,8s,9as,11ar)-1-[(2r,3r)-2,3-dihydroxy-6-methyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-7,8-dihydroxy-9a,11a-dimethyl-1h,2h,4h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-5-one

C33H52O11 (624.3509)


   

(1r,2s,4s,7s,8r,9s,12s,13r,16s,18s,19s)-16-hydroxy-19-{[(2r,4r,5r,6r)-5-hydroxy-6-methyl-4-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6-one

(1r,2s,4s,7s,8r,9s,12s,13r,16s,18s,19s)-16-hydroxy-19-{[(2r,4r,5r,6r)-5-hydroxy-6-methyl-4-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6-one

C33H52O11 (624.3509)


   

n-[(2r)-1-{[(5r,6e,8e,10e,13s,14s,15r,16e)-3,15-dihydroxy-5-methoxy-14,16-dimethyl-22,24-dioxo-2-azabicyclo[18.3.1]tetracosa-1(23),2,6,8,10,16,20-heptaen-13-yl]oxy}-1-oxopropan-2-yl]-4-methylpentanimidic acid

n-[(2r)-1-{[(5r,6e,8e,10e,13s,14s,15r,16e)-3,15-dihydroxy-5-methoxy-14,16-dimethyl-22,24-dioxo-2-azabicyclo[18.3.1]tetracosa-1(23),2,6,8,10,16,20-heptaen-13-yl]oxy}-1-oxopropan-2-yl]-4-methylpentanimidic acid

C35H48N2O8 (624.341)


   

7,9,13-trimethyl-6-[3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-ene-6,11,14,16-tetrol

7,9,13-trimethyl-6-[3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-ene-6,11,14,16-tetrol

C33H52O11 (624.3509)


   

16-hydroxy-19-({5-hydroxy-6-methyl-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6-one

16-hydroxy-19-({5-hydroxy-6-methyl-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6-one

C33H52O11 (624.3509)


   

(20e)-7-butyl-11,16,23,24,25-pentahydroxy-10,19,21-trimethyl-15-methylidene-8,13,28,29-tetraoxatetracyclo[22.3.1.1³,⁶.0¹²,¹⁴]nonacos-20-ene-9,18-dione

(20e)-7-butyl-11,16,23,24,25-pentahydroxy-10,19,21-trimethyl-15-methylidene-8,13,28,29-tetraoxatetracyclo[22.3.1.1³,⁶.0¹²,¹⁴]nonacos-20-ene-9,18-dione

C33H52O11 (624.3509)


   

(1's,2r,2's,5's,6'r,10's,12'r,14's)-5'-[(2s,3r,5r)-5,6-dihydroxy-5,6-dimethyl-3-{[(2r,3r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

(1's,2r,2's,5's,6'r,10's,12'r,14's)-5'-[(2s,3r,5r)-5,6-dihydroxy-5,6-dimethyl-3-{[(2r,3r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

C33H52O11 (624.3509)


   

1-[(1s,3as,3bs,7s,9ar,9bs,11as)-7-{[(2r,4r,5s)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,5r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

1-[(1s,3as,3bs,7s,9ar,9bs,11as)-7-{[(2r,4r,5s)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,5r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

C33H52O11 (624.3509)


   

(1r,2r,3r,4s,5r,6s,7s,8r,10s,11s,14r)-5-(acetyloxy)-14-(butanoyloxy)-6,10-dihydroxy-3-isopropyl-6,10,14-trimethyl-11-(prop-2-enoyloxy)-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate

(1r,2r,3r,4s,5r,6s,7s,8r,10s,11s,14r)-5-(acetyloxy)-14-(butanoyloxy)-6,10-dihydroxy-3-isopropyl-6,10,14-trimethyl-11-(prop-2-enoyloxy)-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate

C33H52O11 (624.3509)